Table 2.
Clinical outcomes in COVID-19 follow-up patients. Data are given as mean ± SD (mean ± standard deviation) and number of patients (percentage). Abbreviations: mMRC, modified Medical Research Council dypnoea scale; EQ-5D-5L, EuroQol - 5 Dimension - 5 Level questionnaire; EQ VAS, EuroQol questionnaire Visual Analogue Scale; * Canary Islands’ general population according to Canary Health Survey 2015 [20].
| POST-COVID CLINICAL MANIFESTATIONS AT FOLLOW-UP | ||||||
| Total (n = 77) | ||||||
| Symptoms, n (%) | 67 (87,0) | |||||
| respiratory variables | ||||||
| – Dyspnea, n (%) | 51 (64,9) | |||||
| mMRC 0 | 26 (33,8) | |||||
| mMRC 1 | 33 (42,9) | |||||
| mMRC 2 | 17 (22,1) | |||||
| mMRC 3 | 1 (1,3) | |||||
| mMRC 4 | 0 (0) | |||||
| – Cough, n (%) | 15 (19,4) | |||||
| – Expectoration, n (%) | 1 (1,3) | |||||
| Non-respiratory variables | ||||||
| – Asthenia, n (%) | 32 (41,5) | |||||
| – Hair loss, n (%) | 24 (31,1) | |||||
| – Arthralgia, n (%) | 20 (25,9) | |||||
| – Ageusia, n (%) | 12 (15,5) | |||||
| – Persistent headache, n (%) | 11 (14,2) | |||||
| – Muscular weakness, n (%) | 11 (14,2) | |||||
| – Myalgia, n (%) – Anxiety, n (%) | 9 (11,6) 8 (10,38) |
|||||
| – Anosmia, n (%) | 7 (9,0) | |||||
| – Memory loss, n (%) | 7 (9,0) | |||||
| – Cramp, n (%) – Menstrual cycle alterations, n (%) – Dysesthesia, n (%) – Dizziness, n (%) – Limbs’ swelling, n (%) | 6 (7,8) 6 (7,8) 4 (5,19) 4 (5,19) 3 (3,89) |
|||||
| POST-COVID CLINICAL MANIFESTATIONS RELATED TO COVID-19 SEVERITY | ||||||
| Mild (n = 17) | Moderate (n = 49) | Severe (n = 11) | P value | |||
| Symptoms,n(%) | 14 (82) | 43 (88) | 10 (91) | 0,779 | ||
| Respiratory symptoms,n(%) | 11 (65) | 33 (67) | 9 (82) | 0,592 | ||
| Non-respiratory symptoms,n(%) | 13 (76) | 37 (75) | 10 (91) | 0,531 | ||
| POST-COVID CLINICAL MANIFESTATIONS RELATED TO GENDER | ||||||
| Male (n = 40) | Female (n = 37) | P value | ||||
| Symptoms, mean ± SD | 2,50 ± 2,07 | 3,75 ± 2,36 | 0,015 | |||
| Respiratory symptoms, mean ± SD | 0,77 ± 0,61 | 0,94 ± 0,74 | 0,275 | |||
| Non-respiratory symptoms, mean ± SD | 1,72 ± 1,70 | 2,81 ± 1,86 | 0,009 | |||
| HEALTH-RELATED QUALITY OF LIFE (5Q-5D-5L QUESTIONNAIRE) RELATED TO GENDER AND AGE GROUP IN 43 COVID-19 FOLLOW-UP PATIENTS COMPARED TO GENERAL POPULATION | ||||||
| COVID-19 follow-up patients (n = 43) | General population* (n = 1.739.088) | P-value | ||||
| Male EQ-VAS, mean ± SD | ||||||
| – Age group < 44 | 63,75 ± 17,02 | 80,03 ± 16,17 | 0,013 | |||
| – Age group 45 – 64 | 82,13 ± 12,55 | 74,34 ± 17,70 | 0,061 | |||
| – Age group > 64 | 67,08 ± 19,12 | 68,51 ± 19,40 | 0,768 | |||
| Female EQ-VAS, mean ± SD | ||||||
| – Age group < 44 | 81,67 ± 7,64 | 77,67 ± 18,33 | 0,593 | |||
| – Age group 45 – 64 | 64,00 ± 20,74 | 70,02 ± 21,38 | 0,260 | |||
| – Age group > 64 | 70,09 ± 18,82 | 61,45 ± 22,01 | 0,128 | |||